Electrocardiographic method for identifying moxifloxacin-induced ventricular repolarization abnormalities

Computers in Cardiology

Volumn 33, Issue , 2006, Pages 705-708

  Couderc, Jean Philippe ^a   Vaglio, M ^a   Xia, X ^a   McNitt, S ^a   Hyrien, O ^a   Zareba, W ^a   Moss, A J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC COMPOUNDS; CARDIOLOGY; CHEMOTHERAPY; CHLORINE COMPOUNDS; DRUG DOSAGE; LEARNING SYSTEMS; TECHNOLOGY;

CARDIOTOXICITY; CLINICAL STUDIES; DRUG-SAFETY; MOXIFLOXACIN; NEW TECHNOLOGIES; REPOLARIZATION; SENSITIVITY AND SPECIFICITY; VENTRICULAR REPOLARIZATION;

DRUG DELIVERY;

EID: 50149117192     PISSN: 02766574     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (7)

1. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. Report No.: DIA meeting, Washington DC, May 2005.
2. Culley CM, Lacy MK, Klutman N, Edwards B. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm 2001 Mar 1;58(5):379-88.
3. Camm AJ, Malik M, Yap YG. Mechanisms of acquired QT prolongation and torsades de pointes. In: Camm AJ, Malik M, Yap YG, editors. Acquired long QT syndrome.London: Blackwell Futura; 2005. p. 8-23.
4. Kutner MH, Natchtsheim CJ, Neter J. Applied Linear Regression Models. 4rd ed. New-York: McGraw-Hill/Irwin; 2004. p. 582-5.
5. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003 Apr 1;58(1):32-45.
6. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996 Dec;28(7):1836-48.
7. Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E, et al. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 2005 Nov;146(6):792-9.